MCID: WLL004
MIFTS: 39

Wallerian Degeneration

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Wallerian Degeneration

MalaCards integrated aliases for Wallerian Degeneration:

Name: Wallerian Degeneration 52 54 71
Wallerian Degeneration of the Pyramidal Tract 52

Classifications:



External Ids:

UMLS 71 C0043020

Summaries for Wallerian Degeneration

MalaCards based summary : Wallerian Degeneration, also known as wallerian degeneration of the pyramidal tract, is related to neuritis and hereditary neuropathies. An important gene associated with Wallerian Degeneration is NMNAT1 (Nicotinamide Nucleotide Adenylyltransferase 1), and among its related pathways/superpathways are Neuroscience and NAD metabolism. The drugs Nitrous oxide and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and cortex, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Wallerian degeneration is an active process of degeneration that results when a nerve fiber is cut or... more...

Related Diseases for Wallerian Degeneration

Diseases related to Wallerian Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 neuritis 30.2 MPZ MAG CNTF
2 hereditary neuropathies 30.1 MPZ MAG
3 peripheral nervous system disease 29.4 VEGFA MPZ MAG ERBB2 CNTF
4 motor neuron disease 28.8 VEGFA NEFM MPZ MAG CNTF
5 spinal cord injury 10.6
6 neuropathy 10.5
7 stroke, ischemic 10.4
8 middle cerebral artery infarction 10.4
9 cytokine deficiency 10.4
10 brain injury 10.3
11 traumatic brain injury 10.3
12 multiple sclerosis 10.2
13 hemiplegia 10.2
14 relapsing-remitting multiple sclerosis 10.2
15 ischemia 10.2
16 cerebrovascular disease 10.2
17 bullous retinoschisis 10.2 VEGFA SARM1
18 amyotrophic lateral sclerosis 1 10.2
19 supranuclear palsy, progressive, 1 10.2
20 charcot-marie-tooth disease 10.2
21 tooth disease 10.2
22 mononeuropathy 10.2
23 spinal muscular atrophy 10.2
24 retinal ischemia 10.2
25 guillain-barre syndrome 10.2
26 lateral sclerosis 10.2
27 temporal lobe epilepsy 10.2
28 scrapie 10.2
29 muscular atrophy 10.2
30 48,xyyy 10.2
31 argyria 10.2
32 primary peritoneal carcinoma 10.1 VEGFA ERBB2
33 autoimmune peripheral neuropathy 10.1 MPZ MAG
34 autoimmune neuropathy 10.1 MPZ MAG
35 lung non-squamous non-small cell carcinoma 10.1 VEGFA ERBB2
36 osteosclerotic myeloma 10.0 VEGFA MAG
37 alzheimer disease 10.0
38 charcot-marie-tooth disease, demyelinating, type 1a 10.0
39 creutzfeldt-jakob disease 10.0
40 huntington disease 10.0
41 hypercholesterolemia, familial, 1 10.0
42 neuropathy, hereditary, with liability to pressure palsies 10.0
43 ocular dominance 10.0
44 polykaryocytosis inducer 10.0
45 triiodothyronine receptor auxiliary protein 10.0
46 krabbe disease 10.0
47 sudanophilic cerebral sclerosis 10.0
48 adrenoleukodystrophy 10.0
49 ataxia and polyneuropathy, adult-onset 10.0
50 charcot-marie-tooth disease, demyelinating, type 1c 10.0

Graphical network of the top 20 diseases related to Wallerian Degeneration:



Diseases related to Wallerian Degeneration

Symptoms & Phenotypes for Wallerian Degeneration

GenomeRNAi Phenotypes related to Wallerian Degeneration according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-3 9.98 ERBB2
2 Decreased viability GR00221-A-4 9.98 ERBB2
3 Decreased viability GR00249-S 9.98 MPZ NMNAT2 NRP2 VEGFA
4 Decreased viability GR00381-A-1 9.98 MPZ NPTX1 PLEKHB1 UBA1
5 Decreased viability GR00381-A-3 9.98 MPZ
6 Decreased viability GR00386-A-1 9.98 MPZ NEFM ODC1 UBE4B
7 Decreased viability GR00402-S-2 9.98 CNTF MPZ ODC1 SARM1 SEMA3F UBA1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.72 CNTF
9 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.72 UBE4B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.72 CNTF SEMA3A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.72 UBE4B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.72 CNTF
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.72 ERBB2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 SEMA3A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-187 9.72 CNTF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 UBE4B
18 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.72 CNTF
19 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.72 UBE4B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.72 UBE4B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 ERBB2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.72 CNTF
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 UBE4B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.72 CNTF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.72 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 ERBB2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.72 ERBB2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.72 UBE4B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.72 CNTF

MGI Mouse Phenotypes related to Wallerian Degeneration:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 CLU CNTF ERBB2 MAG MPZ NMNAT1
2 cellular MP:0005384 9.97 CNTF ERBB2 MPZ NMNAT1 NMNAT2 NRP2
3 muscle MP:0005369 9.5 CLU CNTF ERBB2 NMNAT2 NRP2 UBE4B
4 nervous system MP:0003631 9.5 CLU CNTF ERBB2 MAG MPZ NMNAT1

Drugs & Therapeutics for Wallerian Degeneration

Drugs for Wallerian Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Choline Approved, Nutraceutical Phase 4 62-49-7 305
6 Cytidine Diphosphate Choline Phase 4
7 Adrenergic beta-Agonists Phase 4
8 Adrenergic alpha-Agonists Phase 4
9 Respiratory System Agents Phase 4
10 Anesthetics Phase 4
11 Adrenergic Agents Phase 4
12 Vasoconstrictor Agents Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Adrenergic Agonists Phase 4
15 Epinephryl borate Phase 4
16 Sympathomimetics Phase 4
17 Anesthetics, Local Phase 4
18 Mydriatics Phase 4
19 Bronchodilator Agents Phase 4
20 Neurotransmitter Agents Phase 4
21
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
23
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
24 Trace Elements Phase 2
25 Micronutrients Phase 2
26 Vitamins Phase 2
27 Vitamin B Complex Phase 2
28 Nicotinic Acids Phase 2
29 Vitamin B3 Phase 2
30 Vasodilator Agents Phase 2
31 Folate Phase 2
32 Lipid Regulating Agents Phase 2
33 Nutrients Phase 2
34 Hypolipidemic Agents Phase 2
35 Vitamin B9 Phase 2
36 Antimetabolites Phase 2
37 Pharmaceutical Solutions Phase 1
38 Calamus

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
2 Intercostal Cryoneurolysis Following Traumatic Rib Fractures Enrolling by invitation NCT04198662 Phase 4 Intercostal nerve block ropivacaine with epinephrine
3 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration Not yet recruiting NCT03912220 Phase 2 Nicotinamide riboside;Placebo Oral Tablet
4 Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function Recruiting NCT02359825 Phase 1 Polyethylene glycol (PEG)
5 A Post-Market, Prospective, Randomized, Controlled Study to Evaluate the Iovera° Device Completed NCT03327220
6 FOCAL CORTICAL ATROPHY AFTER MYOCARDIAL INTERNAL CAPSULE: CORRELATION FRACTION ANISOTROPY BEAM PYRAMID AND DISABILITY Completed NCT01862172
7 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
8 Effectiveness of Preoperative Cryoneurolysis (Iovera) for Postoperative Pain Control in Total Knee Arthroplasty Recruiting NCT03818022
9 Cryoneurolysis for the Management of Chronic Pain in Patients With Knee Osteoarthritis; A Randomized Controlled Study Recruiting NCT03774121
10 New Clinical Magnetic Resonance Technologies for Capturing Brain Microstructure Alterations in Patients With Minor Stroke or Transient Ischemic Attack Recruiting NCT04118790
11 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort Recruiting NCT03662750
12 Measuring Active Microglia in Progressive Multiple Sclerosis Active, not recruiting NCT02207075
13 Cryoneurolysis of Arnold's Nerve and Follow-up by Tractography: Feasibility Study Terminated NCT03735914
14 Intercostal Cryoneurolysis Following Traumatic Rib Fractures Terminated NCT03917823

Search NIH Clinical Center for Wallerian Degeneration

Genetic Tests for Wallerian Degeneration

Anatomical Context for Wallerian Degeneration

MalaCards organs/tissues related to Wallerian Degeneration:

40
Spinal Cord, Brain, Cortex, Dorsal Root Ganglion, Bone Marrow, Bone, T Cells

Publications for Wallerian Degeneration

Articles related to Wallerian Degeneration:

(show top 50) (show all 2167)
# Title Authors PMID Year
1
Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. 61 54
20126265 2010
2
Protection of vincristine-induced neuropathy by WldS expression and the independence of the activity of Nmnat1. 61 54
17113230 2007
3
Sequential loss of myelin proteins during Wallerian degeneration in the human spinal cord. 61 54
15634734 2005
4
Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. 61 54
9633807 1998
5
Central neuron-glial and glial-glial interactions following axon injury. 61 54
9602498 1998
6
Nerve expansion in nerve regeneration: effect of time on induction of ornithine decarboxylase and Schwann cell proliferation. 61 54
9324090 1997
7
Transient expression of the neurofilament proteins NF-L and NF-M by Schwann cells is regulated by axonal contact. 54 61
9373038 1997
8
Role of ornithine decarboxylase in proliferation of Schwann cells during Wallerian degeneration and its enhancement by nerve expansion. 54 61
7565936 1995
9
Temporal and spatial expression of ciliary neurotrophic factor after peripheral nerve injury. 54 61
8339774 1993
10
Expression of recombinant myelin-associated glycoprotein in primary Schwann cells promotes the initial investment of axons by myelinating Schwann cells. 61 54
1697293 1990
11
Resveratrol regulates the recovery of rat sciatic nerve crush injury by promoting the autophagy of Schwann cells. 61
32531375 2020
12
Reduced inflammatory response and accelerated functional recovery following sciatic nerve crush lesion in CXCR3-deficient mice. 61
32398421 2020
13
Successful and Complete Recovery of the Ulnar Nerve After Eight Years of Chronic Injury Through Local Steroid Injections: A Case Report. 61
31900814 2020
14
Protein Kinase Cα Promotes Proliferation and Migration of Schwann Cells by Activating ERK Signaling Pathway. 61
32171817 2020
15
Microstructural white matter changes following gait training with Hybrid Assistive Limb initiated within 1 week of stroke onset. 61
32480076 2020
16
Conditioning Electrical Stimulation Accelerates Regeneration in Nerve Transfers. 61
32447758 2020
17
Transaxonal degenerations of cerebellar connections: the value of anatomical knowledge. 61
32490959 2020
18
Intoxication by Astragalus garbancillo var. garbancillo in llamas. 61
32233843 2020
19
Corticospinal Wallerian Degeneration Before Myelination: A Case Report. 61
32406814 2020
20
Compound muscle action potential scan and MScanFit motor unit number estimation during Wallerian degeneration after nerve transections. 61
32415858 2020
21
A Reproducible New Model of Focal Ischemic Injury in the Marmoset Monkey: MRI and Behavioural Follow-Up. 61
32249405 2020
22
Programmed axon degeneration: from mouse to mechanism to medicine. 61
32152523 2020
23
Another umbrella murder? - A rare case of Minamata disease. 61
32323188 2020
24
Synaptic withdrawal following nerve injury is influenced by postnatal maturity, muscle-specific properties, and the presence of underlying pathology in mice. 61
32311115 2020
25
Bidirectional Regulation of Sleep and Synapse Pruning after Neural Injury. 61
32142703 2020
26
Sleep Regulates Glial Plasticity and Expression of the Engulfment Receptor Draper Following Neural Injury. 61
32142708 2020
27
Examination of the human motor endplate after brachial plexus injury with two-photon microscopy. 61
31820462 2020
28
Network diffusion modeling predicts neurodegeneration in traumatic brain injury. 61
32105414 2020
29
Protein microarray analysis of cytokine expression changes in distal stumps after sciatic nerve transection. 61
31571662 2020
30
Wallerian degeneration of bilateral cerebral peduncles after acute carbon monoxide poisoning. 61
32183727 2020
31
Collapsin Response Mediator Protein 4 (CRMP4) Facilitates Wallerian Degeneration and Axon Regeneration following Sciatic Nerve Injury. 61
32001550 2020
32
Different protein expression patterns in rat spinal nerves during Wallerian degeneration assessed using isobaric tags for relative and absolute quantitation proteomics profiling. 61
31552905 2020
33
Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. 61
31740269 2020
34
Organotypic Culture Assay for Neuromuscular Synaptic Degeneration and Function. 61
32524478 2020
35
Loss of highwire Protects Against the Deleterious Effects of Traumatic Brain Injury in Drosophila Melanogaster. 61
32477254 2020
36
Detection of Neutrophils in the Sciatic Nerve Following Peripheral Nerve Injury. 61
32524483 2020
37
Histological and ultrastructural study of AflatoxinB1 induced neurotoxicity in Sciatic nerve of adult male Albino rats. 61
31893473 2020
38
Cytotoxic Immunity in Peripheral Nerve Injury and Pain. 61
32153361 2020
39
Ex Vivo Analysis of Axonal Degeneration Using Sciatic and Optic Nerve Preparations. 61
32524481 2020
40
Prostaglandin D2 synthase modulates macrophage activity and accumulation in injured peripheral nerves. 61
31479164 2020
41
Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases. 61
31761689 2020
42
Radiation induced Wallerian degeneration of corticospinal tract in a case of brain tumour. 61
31954053 2020
43
Wallerian Degeneration of the Cerebral Peduncle and Association with Motor Outcome in Childhood Stroke. 61
31607421 2020
44
Genetic changes in rat proximal nerve stumps after sciatic nerve transection. 61
32042779 2019
45
Deletion of SIRPα (signal regulatory protein-α) promotes phagocytic clearance of myelin debris in Wallerian degeneration, axon regeneration, and recovery from nerve injury. 61
31883525 2019
46
Magnetic resonance imaging evaluation of Wallerian degeneration of bilateral middle cerebellar peduncles after pontine infarction. 61
31828281 2019
47
Differential gene and protein expression between rat tibial nerve and common peroneal nerve during Wallerian degeneration. 61
31397358 2019
48
Wallerian degeneration as a therapeutic target in traumatic brain injury. 61
31633494 2019
49
Peripheral Nerve Injuries: Electrophysiology for the Neurosurgeon. 61
31857526 2019
50
Histological validation of per-bundle water diffusion metrics within a region of fiber crossing following axonal degeneration. 61
31326575 2019

Variations for Wallerian Degeneration

Expression for Wallerian Degeneration

Search GEO for disease gene expression data for Wallerian Degeneration.

Pathways for Wallerian Degeneration

Pathways related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 NRP2 NEFM MAG CLU
2
Show member pathways
11.46 SIRT2 NMNAT2 NMNAT1
3 10.7 VEGFA NEFM CNTF

GO Terms for Wallerian Degeneration

Cellular components related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.43 SEMA3A SARM1 NRP2 NMNAT2 NEFM CNTF
2 paranode region of axon GO:0033270 9.32 SIRT2 MAG
3 Schmidt-Lanterman incisure GO:0043220 9.26 SIRT2 MAG
4 neurofibrillary tangle GO:0097418 9.16 NEFM CLU
5 myelin sheath GO:0043209 8.92 SIRT2 MPZ MAG ERBB2

Biological processes related to Wallerian Degeneration according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 10.09 VEGFA SIRT2 SEMA3A SARM1 NRP2 CNTF
2 neural crest cell migration GO:0001755 9.72 SEMA3F SEMA3A NRP2
3 negative chemotaxis GO:0050919 9.71 SEMA3F SEMA3A NRP2
4 semaphorin-plexin signaling pathway GO:0071526 9.7 SEMA3F SEMA3A NRP2
5 nerve development GO:0021675 9.65 SEMA3F SEMA3A NRP2
6 regulation of postsynapse organization GO:0099175 9.64 SEMA3F NRP2
7 negative regulation of axon extension GO:0030517 9.64 SEMA3A MAG
8 regulation of neuron death GO:1901214 9.63 SARM1 CLU
9 nucleotide biosynthetic process GO:0009165 9.63 NMNAT2 NMNAT1
10 sympathetic ganglion development GO:0061549 9.63 SEMA3F SEMA3A NRP2
11 vascular endothelial growth factor signaling pathway GO:0038084 9.62 VEGFA NRP2
12 NAD metabolic process GO:0019674 9.62 NMNAT2 NMNAT1
13 NAD biosynthetic process GO:0009435 9.61 NMNAT2 NMNAT1
14 facial nerve structural organization GO:0021612 9.61 SEMA3F SEMA3A NRP2
15 semaphorin-plexin signaling pathway involved in axon guidance GO:1902287 9.6 SEMA3F SEMA3A
16 pyridine nucleotide biosynthetic process GO:0019363 9.59 NMNAT2 NMNAT1
17 axonogenesis involved in innervation GO:0060385 9.58 SEMA3A NPTX1
18 branchiomotor neuron axon guidance GO:0021785 9.58 SEMA3F SEMA3A
19 axon extension involved in axon guidance GO:0048846 9.58 SEMA3F SEMA3A NRP2
20 trigeminal ganglion development GO:0061551 9.57 SEMA3A NRP2
21 trigeminal nerve structural organization GO:0021637 9.56 SEMA3F SEMA3A
22 neural crest cell migration involved in autonomic nervous system development GO:1901166 9.54 SEMA3F SEMA3A NRP2
23 facioacoustic ganglion development GO:1903375 9.51 SEMA3A NRP2
24 semaphorin-plexin signaling pathway involved in neuron projection guidance GO:1902285 9.5 SEMA3F SEMA3A NRP2
25 gonadotrophin-releasing hormone neuronal migration to the hypothalamus GO:0021828 9.49 SEMA3A NRP2
26 sympathetic neuron projection guidance GO:0097491 9.43 SEMA3F SEMA3A NRP2
27 sympathetic neuron projection extension GO:0097490 9.33 SEMA3F SEMA3A NRP2
28 nervous system development GO:0007399 9.23 VEGFA SIRT2 SEMA3A SARM1 NRP2 MAG
29 ventral trunk neural crest cell migration GO:0036486 9.13 SEMA3F SEMA3A NRP2

Molecular functions related to Wallerian Degeneration according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nicotinate-nucleotide adenylyltransferase activity GO:0004515 8.96 NMNAT2 NMNAT1
2 nicotinamide-nucleotide adenylyltransferase activity GO:0000309 8.62 NMNAT2 NMNAT1

Sources for Wallerian Degeneration

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....